MediPharm Labs (OTCQX:MEDIF) announce that it has entered into an agreement with Cantor Fitzgerald Canada, as lead underwriter and sole bookrunner on behalf of a syndicate of underwriters, to purchase, on a bought deal basis, 34.5M units at a price of $0.58/unit for gross proceeds of $20M.

MediPharm Labs (OTCQX:MEDIF)宣布，已与作为主承销商和代表一个承销商财团的唯一簿册管理人Cantor Fitzgerald Canada达成协议，将以购买交易的方式，以每单位0.58美元的价格购买3450万份，总收益为2000万美元。

Each unit will be comprised of one share and one share purchase warrant, with each warrant exercisable at $0.70/share for a period of 24 months from the closing date of the offering.

每单位将由一股及一股购买权证组成，每股权证可以$0.70/股的价格执行，期限由发售截止日期起计24个月。

The company has also granted the underwriters an option to purchase up to an additional 5.17M units. The Offering is expected to close on or about March 5, 2021.

该公司还授予承销商最多可额外购买517万辆汽车的选择权。ipo预计将于2021年3月5日或左右结束。

MediPharm plans to use the net proceeds from the offering to fund growth of the company’s Cannabis 2.0 product portfolio, expand medical products and Active Pharmaceutical Ingredient portfolio for export, among other things.

MediPharm计划利用此次发行的净收益为公司大麻2.0产品组合的增长提供资金，扩大用于出口的医疗产品和活性药物成分组合等。